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Introduction
Patients with cardiomyopathy may present with heart failure, arrhythmia or syncope; cardiomyopathies are also the leading causes of sudden cardiac death in persons <50 years of age. However, if cardiomyopathy is diagnosed early, potentially fatal complications can be prevented by means of medical treatment or device implantation. 1, 2 Cardiomyopathies in younger persons, including the hypertrophic, dilated, restrictive and arrhythmogenic right ventricular cardiomyopathies, show evidence of familial aggregation, 3 with autosomal dominance the most frequent pattern of inheritance. 4 Accordingly, the clinical workup of cardiomyopathy patients includes eliciting any history of cardiomyopathy in family members and screening relatives with unknown cardiomyopathy status.
North American and European guidelines for screening of the relatives of cardiomyopathy patients are predominantly based on the findings of studies conducted at tertiary referral centers. 5, 6 Not surprisingly, these studies are characterized by small sample sizes, an absence of "control" families, a focus on highly-selected cases and heavily-affected families, and self-reported family histories. 7 While the study results undoubtedly reflect reality among families with the most severe cardiomyopathy phenotypes and the greatest burden of cardiomyopathy, their generalizability to the general population subject to current screening protocols is unclear and there is a consensus in the cardiology community that population-based studies of the familial aggregation of cardiomyopathy are needed. [6] [7] [8] Using the Danish population as our cohort, we examined the degree to which cardiomyopathy in younger persons (<50 years) aggregates in families at the population level, by comparing the rate of cardiomyopathy in younger persons with a relative who died prematurely (<60 years) from cardiomyopathy (a very severe cardiomyopathy phenotype) with the rate of unknown cardiomyopathy status.
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Methods

Data sources
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Study cohort, identification of relatives and assessment of premature deaths among relatives
The study cohort included all residents of Denmark who 1) were born in 1950-1977 and were still alive on January 1, 1978, or who were born thereafter, and 2) had at least one identifiable relative in the Danish Family Relations Database. For each cohort member, we used the Danish Family Relations Database to identify first-and second-degree relatives. We then identified premature deaths (death occurring before age 60 years) in relatives using the Causes of Death
Register.
Premature cardiac deaths were defined as deaths < 60 years with death certificate causes of death that included ICD-8 codes 390.00-429.99 or ICD-10 codes I00-I51. Premature deaths with none of these cardiac codes on the death certificate were classified as premature non-cardiac deaths. As we have done previously, we excluded deaths that might possibly have been misclassified cardiac deaths (deaths due to stroke, cerebral hemorrhage, asthma, epilepsy, solo accidents and unexplained causes) from both the cardiac and non-cardiac categories. 12 We also examined two specific sub-groups of cardiac death: premature deaths from ischemic heart disease (ICD-8 codes 410-414.99 and ICD-10 codes I20-I25.9) and premature deaths from cardiomyopathy (ICD-8 code 425.99 and ICD-10 codes I42-I43.8). Since ischemic heart disease can produce secondary cardiomyopathy, persons with both ischemic heart disease and cardiomyopathy diagnoses on the death certificate were classified as having died of ischemic heart disease. A death was presumed to be due to cardiomyopathy only in the absence of an ischemic heart disease diagnosis on the death certificate, resulting in a very conservative definition of premature deaths from cardiomyopathy.
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Assignment of exposure status
Family history of premature death was considered as a time-dependent variable. A cohort member was classified as exposed from the date of death of the first relative (if any) to die from the type of premature death in question (non-cardiac, any cardiac, ischemic, cardiomyopathy). If the premature death occurred before birth of the cohort member, the cohort member was considered exposed from birth. If there were no premature deaths in a cohort member's family, all follow-up time was classified as unexposed.
Outcome
Persons diagnosed with cardiomyopathy during follow-up (ICD-8 code 425.99; ICD-10 codes I42-I43.8 -see Table 1 for a description of the cardiomyopathy subtypes covered by these ICD- Poisson regression, we estimated incidence rate ratios (IRRs) comparing the rate of for cardiomyopathy among those with a relative who died before age 60 years compared with those with no such relatives; we estimated separate IRRs for non-cardiac premature deaths and the three types of premature cardiac death (any cardiac death, death due to ischemic heart disease, and death due to cardiomyopathy). We also examined associations with premature death by kinship degree (first-or second-degree), number of affected relatives (1 or 2), relative's age at death, cohort member attained age, and relative type (parent, sibling, grandparent, half-sibling, uncle/aunt). Finally, we estimated IRRs for associations between premature cardiomyopathy deaths in first-and second-degree relatives and rates of ventricular arrhythmia.
In relative-specific analyses, we compared only individuals having the same kind of relatives to reduce any bias that might result from incomplete identification of family members Tests were based on Wald statistics and analyses were performed using proc genmod in the SAS software.
Ethics
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Results
Our cohort included 3,985,301 persons followed for 89,272,960 person-years. Of these, 34,362 had at least one relative who died prematurely of cardiac causes. Of those with a family history of premature cardiac death, 27,162 had a family history of premature death due to ischemic heart disease, while 778 had one or more premature cardiomyopathy deaths in the family. In contrast, 223,349 persons had a family history of premature death due to non-cardiac causes.
During follow-up, 3,890 persons were diagnosed with cardiomyopathy; the median age at diagnosis was 38 years. Table 2 shows the distribution of sex and age at diagnosis for those registered with cardiomyopathy during the follow-up period.
Associations between family history of premature death and rate of cardiomyopathy (Table 3)
Persons <50 years of age with a first-degree relative who died prematurely of any cardiac cause had a rate of cardiomyopathy that was almost 3 times higher than that in persons with no such family history, while persons with a history of premature cardiac death in a second-degree relative had a 58% increase in cardiomyopathy rate. Persons who specifically had a history of premature cardiomyopathy death in a first-degree relative were 30 times as likely as persons with no premature cardiomyopathy deaths among first-degree relatives to be diagnosed with cardiomyopathy before 50 years of age. Even a history of premature cardiomyopathy death in a second-degree relative was associated with a 6-fold increase in the rate of cardiomyopathy. In comparison, premature deaths in first-degree relatives due to ischemic heart disease were associated with a 2-fold increase in the rate of cardiomyopathy. Premature non-cardiac deaths in first-degree relatives were only associated with a 24% increase in the rate of cardiomyopathy.
Associations between family history of premature death from cardiomyopathy and rate of cardiomyopathy, by sex, age and relative's age at death
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Persons <50 years of age with a first-degree relative who died prematurely of any cardiac cause had a a a ra ra rate te te o o of f f ca c rd d dio io iomyopathy that was almost 3 t t ti i ime me m s higher than that i i in n n pe p p rsons with no such Since congenital heart disease might be misclassified as cardiomyopathy, we also conducted a sub-analysis restricted to cohort members 10 years of age. In this analysis, IRRs for cardiomyopathy before age 50 years were 27.8 (95% CI 20.9-37.0) for a history of premature death from cardiomyopathy in a first-degree relative and 16.0 (95% CI 7.13-35.8) for those with such a history in a second-degree relative. Table 4 shows the effect of first-degree relative age at death and cohort member attained age on the IRR for cardiomyopathy. Attained age <35 years and age at relative death <35 years were both particularly strongly associated with cardiomyopathy rate ( Table 4 ). If a first-degree relative died from cardiomyopathy at <35 years of age, the rate of cardiomyopathy increased up to 100-fold, but even cardiomyopathy deaths in older relatives were associated with dramatic increases in cardiomyopathy rates ( Table 4 ).
Associations between number of premature cardiomyopathy deaths in the family and rate of cardiomyopathy
The strength of the association depended on the number of relatives who died prematurely from cardiomyopathy ( Table 5) 
Discussion
This is the first large, population-based study to examine the risk of cardiomyopathy before age 50 years associated with a family history of premature death from cardiomyopathy. Any premature cardiac death in a first-degree relative was associated with an almost 3-fold increase in the rate of were also associated with modestly increased rates of cardiomyopathy. If a first-degree relative died specifically of cardiomyopathy, the rate of cardiomyopathy before age 50 years increased by a markedly 30-fold, and even cardiomyopathy deaths in second-degree relatives were associated with a 6-fold increase in the rate of cardiomyopathy. In contrast, ischemic heart disease deaths in first-degree relatives were associated with only a 2-fold increase in cardiomyopathy rate and noncardiac deaths increased the rate of cardiomyopathy very little (24%).
The association between a history of premature cardiomyopathy death in first-degree relatives and cardiomyopathy rates appeared to be stronger for women than men. The rate of cardiomyopathy increased even more if the cardiomyopathy death in the first-degree relative occurred before 35 years of age (>100-fold increase in rate), and if 2 first-degree relatives had died from cardiomyopathy, the rate of cardiomyopathy increased more than 400-fold.
Cardiomyopathy deaths in second-degree relatives were also associated with increases in cardiomyopathy rates, although to a lesser extent (5-to 65-fold increases). We also found significant increases in ventricular arrhythmia rates in those with a family history of premature death from cardiomyopathy among first-or second-degree relatives.
Our results show that the strong familial aggregation of cardiomyopathy demonstrated in case studies of selected families identified by tertiary referral institutions, also holds in the general population; associations between a family history of premature death and risk of cardiomyopathy were most dramatic for familial cardiomyopathy deaths and were much weaker for ischemic and other cardiac deaths. Deaths in first-degree relatives were much more strongly associated with cardiomyopathy risk than deaths in second-degree relatives (although risks associated with these deaths were by no means inconsiderable), consistent with the proportion of shared genes among first-and second-degree relatives and the genetic inheritance of an occurred before 35 years of age (>100-fold increase in rate), and if 2 first-degree e e r r rel el elat at ativ iv ives es es h h had ad ad died from cardiomyopathy, the rate of cardiomyopathy increased more than 400-fold. 
Clinical Implications
The observed increases in risk of clinically diagnosed cardiomyopathy (ranging from 6-to 400fold) in persons with a family history of premature cardiomyopathy death strongly support the present recommendations for pre-symptomatic screening in families with cardiomyopathy.
Ventricular arrhythmia is a life-threatening complication of cardiomyopathy and may be the first symptom of disease. The observed 3-to 7-fold increased risk of ventricular tachycardia in persons with a family history of premature death from cardiomyopathy further underlines the importance of pre-symptomatic screening and early intervention.
Our ability to grade the risk depending on age at clinical manifestations in the proband and kinship, gender and number of affected family members may allow for more detailed recommendations regarding when to initiate screening and risk assessment in individual relatives.
A vast number of cardiomyopathy-causing mutations have been identified to date 13, 14 , making genetic testing a useful tool for identifying relatives at risk of developing cardiomyopathy due to cardiomyopathy in a relative; if a disease-causing mutation can be identified in a family, family members who are not carriers can be excluded from further followup. However, in up to 50% of families screened, no disease-causing mutation can be identified in the proband, 8, 14 and no genetic differentiation between at-risk relatives and those who are riskfree is possible. In these families, all relatives need clinical follow-up. Furthermore, genetic testing may be a challenging and expensive process in some settings.
Our study identified elements of family history that could be useful for grading risk in persons with a family history of cardiomyopathy death. The overwhelming associations between Our ability to grade the risk depending on age at clinical manifestations in n n th th the e e pr pr prob ob oban an and d d and kinship, gender and number of affected family members may allow for more detailed eco omm mm mmen en enda da dati t t on n ns re r r garding when to initiate scre re een en enin i i g and risk assessm m men en nt in individual e e ela a atives.
A va a ast st st num um umber r r o of o car r rdi di dio om o yo yo yopa pa ath h hy-y y ca ca cau u using g g mu mu muta ta tat t tion n ns ha ha h v v ve bee e e n n n iden n nti tifi f f ed t t to o o dat te 1 1 13,14 , , , ma ma maki ki king ng ng g g gen en enet et etic ic ic t t tes es esti ti ting ng ng a a a use se sefu f ful l l to to tool ol ol f f for or or i i id d den en enti ti tify f fyin in ing g g re re rela la lati ti tive e ves s s at at at r r ris is isk k k of of of d d dev e evel el elop op opin in ing g g t t t very early (<35 years of age) cardiomyopathy death in a first-degree relative and risk of cardiomyopathy in all age groups suggest that anyone with this family history has an exceptionally strong predisposition to a very serious cardiomyopathy phenotype. Furthermore, our finding that cardiomyopathy risk was "dose-dependent", increasing with increasing number of affected relatives for both first-and second-degree relatives, indicates that persons with more than one cardiomyopathy death in the family, even if these deaths are "only" in second-degree relatives, are at very high risk of cardiomyopathy.
Our study identified approximately 4,000 patients registered with cardiomyopathy, among nearly 4 million persons. Assuming this number corresponds to an overall cardiomyopathy prevalence of 1:1000, it is interesting to compare this number to the generally reported prevalences for the most frequent cardiomyopathies: hypertrophic cardiomyopathy, 1:500 6 ; dilated cardiomyopathy, 1:2,500 15 ; and arrhythmogenic right ventricular cardiomyopathy, 1:2,000-1:5,000 16 -for a combined prevalence of 2:1.000-3:1,000. Considering that clinically confirmed hypertrophic cardiomyopathy is often reported considerably lower than 1:500, due to cardiomyopathies being subclinical or under-or misdiagnosed 17, 18 , our observed cardiomyopathy prevalence and the reported prevalences seem to be in reasonable accordance.
The remaining discrepancy may reflect that pre-symptomatic family screening in Denmark has not been completely effective.
Potential Limitations and Strengths
Despite its enormous size and use of Danish register data, our study had some potential limitations. We were forced to consider all cardiomyopathies as a single disease entity due to a lack of clinical information (e.g. septum thickness, ejection fraction, genotype) and to the very limited level of detail in registered diagnosis codes, particularly before 1994 when the ICD-8 cardiomyopathy prevalence of 1:1000, it is interesting to compare this number to th th the e e ge ge gene ne nera ra rall ll lly y y eported prevalences for the most frequent cardiomyopathies: hypertrophic cardiomyopathy, 1:50 0 00 0 0 6 ; ; ; di di dila la late te ted ca ca ard rd rdiomyopathy, 1:2,500 15 ; and ar ar arrh rh rhythmogenic right ven en entr t icular c c card d diomyopathy hy y, , , 1 1:2, 2 2 00 00 000-0-0-1: 1: 1:5, 5, 5,00 00 000 0 0 16 system, which had only a single cardiomyopathy code, was used. Even after 1994, when the ICD-10 system offered the potential for more detailed diagnoses, a considerable proportion (39%) of cardiomyopathy diagnoses in the Hospital Discharge Register were non-specific ("other" or "unspecified" cardiomyopathy) ( Table 1) . On the other hand, recent studies have shown that the same genetic mutations can cause both dilated and hypertrophic cardiomyopathies, and even that cardiomyopathy in an individual can evolve over time from one sub-type to another, such that considering the cardiomyopathies as a combined group seems justified. 19 Cardiomyopathies can be divided into primary cardiomyopathies and cardiomyopathies arising secondary to another condition, with the former clearly of greatest interest in a familial aggregation study such as ours. However, cardiomyopathy subtypes were not available in ICD-8
and a large proportion of cardiomyopathies registered using ICD-10 codes were not subtyped either. We assumed, however, that the bulk of the "unspecified" cardiomyopathies were primary cardiomyopathies, an assumption supported by data from the Hospital Discharge Register showing that from 1994 to 2010, <12% of cardiomyopathies in persons <50 years of age were secondary to another condition (endomyocardial (eosinophilic) cardiomyopathy, endocardial fibroelastosis, alcoholic cardiomyopathy, drug-induced cardiomyopathy, and cardiomyopathy secondary to other diseases), Table 1 . Since these secondary cardiomyopathies are unlikely to be familial, if their inclusion in our study had any effect, it would have been to weaken the magnitude of our familial aggregation estimates.
In the very young, congenital heart disease may initially be misdiagnosed as cardiomyopathy. However, analyses excluding persons aged <10 years produced results similar to our main analyses and in fact, the association between a history of cardiomyopathy death in arising secondary to another condition, with the former clearly of greatest interest t t i i in n n a a a fa fa fami mi mili li lial al al aggregation study such as ours. However, cardiomyopathy subtypes were not available in ICD-8 t and a a a la la larg rg rge e e pr pr propor or orti t t on of cardiomyopathies regist st ster er ered e using IC m m D-10 cod od ode e es were not subtyped ei ei eith h her. We assum um ume ed, h h howe we wev ve ver, r, r, t t tha ha hat th th the e bu ulk k k o of f f the " "u uns s spe pe peci ci cifi fi fied ed ed" " " ca a A not-insubstantial number of cardiomyopathies were almost certainly misclassified as heart failure, particularly early in the study period and before the advent of echocardiography, but also later on, reflecting variations in diagnostic practice at different hospitals. Once again, however, if anything, such misclassification would have weakened the true magnitude of the familial aggregation of cardiomyopathy in our study.
Data on behavioral risk factors for cardiomyopathy, such as alcohol consumption, are unavailable on a nationwide level, and secondary cardiomyopathies could therefore not be excluded. However, the number of cardiomyopathies identified during follow-up that were secondary to ischemic heart disease, alcohol or drug use is likely to have been small relative to the number of primary, familial cardiomyopathies, particularly in the younger age groups that were the focus of our study. Consequently, the lack of behavioral risk factor information is unlikely to have been a problem.
Surveillance bias might have affected our results if relatives of a premature cardiomyopathy death victim were more likely to seek medical attention after the death and be diagnosed with cardiomyopathy than persons without such a death in the family. However, the systematic family screening approach to inherited cardiovascular disease only emerged in Denmark late part in the study period (after 2006 20 ) and thus it seems unlikely that our findings of very high relative risks reflects targeted family workups in tertiary centers at selected hospitals. If surveillance bias was a major problem, we might also have expected to see equally strong associations between other types of premature cardiac deaths in relatives and rates of cardiomyopathy. However, IRRs for associations with cardiac deaths (overall) and ischemic excluded. However, the number of cardiomyopathies identified during follow-up th th that at at w w wer er ere e e econdary to ischemic heart disease, alcohol or drug use is likely to have been small relative to heart disease deaths were not greater than 3, whereas estimates for cardiomyopathy deaths were generally at least ten times larger, suggesting that surveillance bias did not have a major influence on our results.
Major strengths of our study included the large cohort size, our ability to assess family history without contacting study subjects (thus avoiding recall bias), and comparison of exposed and unexposed families (in contrast to typical hospital-based studies). Only clinically diagnosed cased were included. Furthermore, we included associations with premature non-cardiac deaths and other types of cardiac deaths for comparison. Finally, our use of an entire country as our cohort suggests that our findings are likely to be broadly generalizable.
Conclusion
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